title: Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.
abstract: Oncolytics Biotech is developing an oncolytic reovirus therapy (Reolysin, Reosyn) for the potential treatment of a variety of Ras-mediated cancers, including glioma and medulloblastoma, pancreatic, prostate, breast, lung, colon, bladder, ovarian and hematological cancers, and melanoma and childhood sarcoma. Phase I/II clinical trials in recurrent malignant glioma began in 2002.
authors.affiliation: New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Stoeckel
authors.forename: John G
authors.initials: JG
authors.lastname: Hay
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy; D010330:Patents as Topic; D012087:Reoviridae / Q000502:physiology*; D013329:Structure-Activity Relationship